Table 2.
Prevalence and severity of chronic health conditions by CTCAE grade between ALL survivors (N=980) and community controls (N=272) *
| Cardiovascular | Cardiomyopathy | Hypertension | High Cholesterol | Hypertriglyceridemia | |||||||||||||||||
|
ALL Survivors |
Controls | ALL Survivors | Controls | ALL Survivors | Controls |
ALL Survivors |
Controls | ||||||||||||||
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | ||||||
| Normal | 953 | (97∙3) | 270 | (99∙3) | 0∙34 | 453 | (46∙2) | 153 | (56∙3) | 0∙084 | 649 | (66∙2) | 191 | (70∙2) | 0∙58 | 730 | (74∙5) | 219 | (80∙5) | 0∙46 | |
| Grade 1 | -- | -- | -- | -- | 347 | (35∙4) | 79 | (29∙0) | 243 | (24∙8) | 64 | (23∙5) | 200 | (20∙4) | 42 | (15∙4) | |||||
| Grade 2 | 16 | (1∙6) | 1 | (0∙4) | 133 | (13∙6) | 31 | (11∙4) | 83 | (8∙5) | 17 | (6∙3) | 37 | (3∙8) | 10 | (3∙7) | |||||
| Grade 3 | 11 | (1∙1) | 1 | (0∙4) | 47 | (4∙8) | 9 | (3∙3) | 5 | (0∙5) | 0 | (0∙0) | 12 | (1∙2) | 1 | (0∙4) | |||||
| Grade 4 | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | 1 | (0∙1) | 0 | (0∙0) | |||||
| Endocrine/Reproductive | Growth Hormone Deficiency | Adrenal Insufficiency | Hypothyroidism | ||||||||||||||||||
|
ALL Survivors |
Controls | ALL Survivors | Controls | ALL Survivors | Controls | ||||||||||||||||
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | ||||||||||
| Normal | 743 | (75∙8) | 266 | (97∙8) | <0∙0001 | 960 | (98∙0) | 272 | (100) | 0∙26 | 964 | (98∙4) | 259 | (95∙2) | <0∙0035 | ||||||
| Grade 1 | 229 | (23∙4) | 6 | (2∙2) | 12 | (1∙2) | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | |||||||||
| Grade 2 | 8 | (0∙8) | 0 | (0∙0) | 8 | (0∙8) | 0 | (0∙0) | 16 | (1∙6) | 13 | (4∙8) | |||||||||
| Grade 3 | -- | -- | -- | -- | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | |||||||||
| Grade 4 | -- | -- | -- | -- | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | 0 | (0∙0) | |||||||||
| Central Hypogonadism | Primary Hypogonadism (male) | Primary Hypogonadism (female) | Oligospermia/ Azoospermia┼ | ||||||||||||||||||
|
ALL Survivors |
Controls | ALL Survivors | Controls | ALL Survivors | Controls | ALL Survivors | Controls† | ||||||||||||||
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | ||||||
| Normal | 915 | (93∙4) | 272 | (100) | 0∙016 | 426 | (86∙1) | 125 | (96∙2) | <0∙00043 | 445 | (91∙8) | 139 | (97∙9) | 0∙022 | 76 | (32∙3%) | -- | -- | ||
| Grade 1 | 27 | (2∙7) | 0 | (0∙0) | 17 | (3∙4) | 0 | (0∙0) | -- | -- | -- | -- | -- | -- | -- | -- | |||||
| Grade 2 | 38 | (3∙9) | 0 | (0∙0) | 52 | (10∙5) | 0 | (0∙0) | -- | -- | -- | -- | 55 | (23∙4%) | -- | -- | |||||
| Grade 3 | - | - | -- | -- | 0 | (0∙0) | 5 | (3∙8) | 40 | (8∙2) | 3 | (2∙1) | 104 | (44∙3%) | -- | -- | |||||
| Grade 4 | - | - | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | |||||
| Bone Health | Low Bone Mineral Density | Osteonecrosis | Metabolic | Impaired Fasting Glucose | Overweight/Obesity | ||||||||||||||||
|
ALL Survivors |
Controls† | ALL Survivors | Controls† | ALL Survivors | Controls |
ALL Survivors |
Controls | ||||||||||||||
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | ||||||
| Normal | 471 | (48∙1) | -- | -- | 861 | (87∙9) | -- | -- | 790 | (80∙6) | 218 | (80∙2) | 0∙26 | 276 | (28∙2) | 100 | (36∙8) | 0∙13 | |||
| Grade 1 | 394 | (40∙2) | -- | -- | 91 | (9∙3) | -- | -- | 128 | (13∙1) | 43 | (15∙8) | -- | -- | -- | -- | |||||
| Grade 2 | 115 | (11∙7) | -- | -- | 25 | (2∙6) | -- | -- | 44 | (4∙5) | 10 | (3∙7) | 269 | (27∙4) | 69 | (25∙4) | |||||
| Grade 3 | 0 | (0∙0) | -- | -- | 3 | (0∙3) | -- | -- | 18 | (1∙9) | 1 | (0∙4) | 330 | (33∙7) | 78 | (28∙7) | |||||
| Grade 4 | -- | -- | -- | -- | -- | -- | -- | -- | 0 | (0∙0) | 0 | (0∙0) | 105 | (10∙7) | 25 | (9∙2) | |||||
| Neurologic | Peripheral Sensory Neuropatdy | Peripheral Motor Neuropathy | Stroke | Cataract | |||||||||||||||||
|
ALL Survivors |
Controls | ALL Survivors | Controls | ALL Survivors | Controls |
ALL Survivors |
Controls | ||||||||||||||
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | (N) | (%) | ||||||
| Normal | 684 | (69∙8) | 237 | (87∙1) | <0∙0001 | 891 | (90∙9) | 272 | (100) | <0∙0095 | 927 | (94∙6) | 271 | (99∙6) | 0∙16 | 829 | (84∙6) | 250 | (91∙9) | 0∙056 | |
| Grade 1 | 221 | (22∙6) | 30 | (11∙0) | 19 | (1∙9) | 0 | (0∙0) | 6 | (0∙6) | 0 | (0∙0) | 134 | (13∙7) | 19 | (7∙0) | |||||
| Grade 2 | 52 | (5∙3) | 5 | (1∙8) | 50 | (5∙1) | 0 | (0∙0) | 8 | (0∙8) | 0 | (0∙0) | 12 | (1∙2) | 2 | (0∙7) | |||||
| Grade 3 | 23 | (2∙4) | 0 | (0∙0) | 20 | (2∙0) | 0 | (0∙0) | 18 | (1∙9) | 1 | (0∙4) | 4 | (0∙4) | 1 | (0∙4) | |||||
| Grade 4 | -- | -- | -- | -- | - | - | -- | -- | 21 | (2∙1) | 0 | (0∙0) | 1 | (0∙1) | 0 | (0∙0) | |||||
*
adjusted for gender, age, and race
┼
assessed only among consenting males (n=235)
†
not assessed among controls